Skip to main content
. Author manuscript; available in PMC: 2009 Nov 5.
Published in final edited form as: J Natl Cancer Inst. 2008 Oct 28;100(21):1500–1510. doi: 10.1093/jnci/djn351

Figure 1.

Figure 1

Activity of tamoxifen in human tumor xenografts in mice. A) MDA-MB-435 estrogen receptor–negative melanoma xenografts. B) MDA-MB-361 estrogen receptor–positive xenografts. Cells of both lines were implanted orthotopically into the mammary fat pad of athymic nu/nu NCr mice (Animal Production Program, NCI-Frederick), and treatment was initiated when the tumors reached 150–175 mg in size. The MDA-MB-361 tumor–bearing mice were treated weekly with estradiol cypionate (20 μg/mouse) to support tumor growth. Exogenous estradiol is not required for progressive growth of MDA-MB-435 xenografts. For both studies the vehicle control was 100% sesame oil given by oral gavage once daily for 20 days (n=20 mice). Tamoxifen was administered by oral gavage once daily for 20 days at a dose of 45, 22.5, or 11.25 mg/kg (n=10 mice per dose). Individual tumor weights were calculated as weight in mg = [length × width2]/2. Data are plotted as median tumor weight +/− the 95% confidence interval of the median.